Aytu BioPharma, Inc. (NasdaqCM: AYTU)
Health Care · Pharmaceuticals · US
$2.35
-0.84% today · +3.3% 1Y
Aytu BioPharma, Inc. (NasdaqCM: AYTU) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $25.44M and employs 83 people.
Over the last twelve months the share price has gained 3.3%, trading between 1.65 and 3.07.
Tweenvest scores Aytu BioPharma, Inc. across four factors: quality 50/100, value 47/100, growth 65/100. Its strongest factor is growth.
AYTU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.44M
- Revenue (TTM)
- $56.60M
- P/E
- —
- EPS
- -3.71
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- $3.07
- 52-week low
- $1.65
- Avg volume (3M)
- —
- Shares outstanding
- 10.73M
- Employees
- 83
- Next earnings
- —
About Aytu BioPharma, Inc.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
- ISIN
- US0547548588
- Listed since
- Sep 25, 2008
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.50 | -0.01% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.20 | +0.02% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.